{"a":[{"_":"Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice","$":{"href":"/research/artelos-ex-astrazeneca-cannabinoid-agonist-holds-its-own-against-glp1s-obese-mice","hreflang":"en"}}]}

Data ReadoutpositiveOral dual cannabinoid agonistsemaglutidePositive

AI Analysis

Summary

Artelo Biosciences' oral dual cannabinoid agonist demonstrated weight loss results comparable to semaglutide in obese mice models. The preclinical data suggests potential competitive positioning against GLP-1 drugs in the obesity treatment space.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Artelo's cannabinoid agonist showed weight loss comparable to GLP-1 semaglutide in obese mice

Importance:5/10

Sentiment:

0.60

cannabinoidweight lossobesitypreclinicalGLP-1 comparison

Related Companies

$ARTL $AZN

Read the original article

Published by FierceBiotech on September 18, 2026 2:24 PM

Read Original